Cargando…
Virus-like particles: The new frontier of vaccines for animal viral infections
Vaccination continues to be the main approach to protect animals from infectious diseases. Until recently, all licensed vaccines were developed using conventional technologies. Subunit vaccines are, however, gaining attention from researchers in the field of veterinary vaccinology, and among these,...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112581/ https://www.ncbi.nlm.nih.gov/pubmed/22705417 http://dx.doi.org/10.1016/j.vetimm.2012.04.026 |
_version_ | 1783513501369630720 |
---|---|
author | Crisci, Elisa Bárcena, Juan Montoya, María |
author_facet | Crisci, Elisa Bárcena, Juan Montoya, María |
author_sort | Crisci, Elisa |
collection | PubMed |
description | Vaccination continues to be the main approach to protect animals from infectious diseases. Until recently, all licensed vaccines were developed using conventional technologies. Subunit vaccines are, however, gaining attention from researchers in the field of veterinary vaccinology, and among these, virus-like particles (VLPs) represent one of the most appealing approaches. VLPs are robust protein cages in the nanometer range that mimic the overall structure of the native virions but lack the viral genome. They are often antigenically indistinguishable from the virus from which they were derived and present important advantages in terms of safety. VLPs can stimulate strong humoral and cellular immune responses and have been shown to exhibit self-adjuvanting abilities. In addition to their suitability as a vaccine for the homologous virus from which they are derived, VLPs can also be used as vectors for the multimeric presentation of foreign antigens. VLPs have therefore shown dramatic effectiveness as candidate vaccines. Here, we review the current status of VLPs as a vaccine technology in the veterinary field, and discuss the potential advantages and challenges of this technology. |
format | Online Article Text |
id | pubmed-7112581 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71125812020-04-02 Virus-like particles: The new frontier of vaccines for animal viral infections Crisci, Elisa Bárcena, Juan Montoya, María Vet Immunol Immunopathol Article Vaccination continues to be the main approach to protect animals from infectious diseases. Until recently, all licensed vaccines were developed using conventional technologies. Subunit vaccines are, however, gaining attention from researchers in the field of veterinary vaccinology, and among these, virus-like particles (VLPs) represent one of the most appealing approaches. VLPs are robust protein cages in the nanometer range that mimic the overall structure of the native virions but lack the viral genome. They are often antigenically indistinguishable from the virus from which they were derived and present important advantages in terms of safety. VLPs can stimulate strong humoral and cellular immune responses and have been shown to exhibit self-adjuvanting abilities. In addition to their suitability as a vaccine for the homologous virus from which they are derived, VLPs can also be used as vectors for the multimeric presentation of foreign antigens. VLPs have therefore shown dramatic effectiveness as candidate vaccines. Here, we review the current status of VLPs as a vaccine technology in the veterinary field, and discuss the potential advantages and challenges of this technology. Elsevier B.V. 2012-08-15 2012-05-31 /pmc/articles/PMC7112581/ /pubmed/22705417 http://dx.doi.org/10.1016/j.vetimm.2012.04.026 Text en Copyright © 2012 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Crisci, Elisa Bárcena, Juan Montoya, María Virus-like particles: The new frontier of vaccines for animal viral infections |
title | Virus-like particles: The new frontier of vaccines for animal viral infections |
title_full | Virus-like particles: The new frontier of vaccines for animal viral infections |
title_fullStr | Virus-like particles: The new frontier of vaccines for animal viral infections |
title_full_unstemmed | Virus-like particles: The new frontier of vaccines for animal viral infections |
title_short | Virus-like particles: The new frontier of vaccines for animal viral infections |
title_sort | virus-like particles: the new frontier of vaccines for animal viral infections |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112581/ https://www.ncbi.nlm.nih.gov/pubmed/22705417 http://dx.doi.org/10.1016/j.vetimm.2012.04.026 |
work_keys_str_mv | AT criscielisa viruslikeparticlesthenewfrontierofvaccinesforanimalviralinfections AT barcenajuan viruslikeparticlesthenewfrontierofvaccinesforanimalviralinfections AT montoyamaria viruslikeparticlesthenewfrontierofvaccinesforanimalviralinfections |